![Peter Davies](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Davies
Director/Board Member at
Bionomics Ltd.
Net worth: 24 596 $ as of 30/09/2026
Profile
Mr. Peter M.
Davies is an Independent Non-Executive Director at Neuphoria Therapeutics, Inc., an Independent Non-Executive Director at Bionomics Ltd. and a Chief Business Officer at Leaf4life, Inc. He is on the Board of Directors at Neuphoria Therapeutics, Inc. and Bionomics Ltd. Mr. Davies was previously employed as a Managing Director by Apeiron Investment Group Ltd. He received his graduate degree from The University of Edinburgh.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0.13% | 17/09/2026 | 6,909 ( 0.13% ) | 24 596 $ | 30/09/2026 |
Peter Davies active positions
| Companies | Position | Start |
|---|---|---|
Bionomics Ltd.
 Bionomics Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutics for cancer and diseases of the central nervous system | Director/Board Member | 01/07/2021 |
Leaf4life, Inc.
 Leaf4life, Inc. Miscellaneous Commercial ServicesCommercial Services LEAF4Life specializes in developing medicines targeting hypoxia-related disorders. The private company is based in Woburn, MA. The company's lead product, LEAF-4L6715, is a proprietary liposomal formulation of transcrocetin aimed at enhancing oxygen diffusion in patients with conditions such as acute respiratory distress syndrome (ARDS), cancer, and cardiovascular diseases. | Corporate Officer/Principal | - |
Former positions of Peter Davies
| Companies | Position | End |
|---|---|---|
Apeiron Investment Group Ltd.
 Apeiron Investment Group Ltd. Investment ManagersFinance Apeiron Investment Group invests in both public and private companies located across the globe primarily in the United States. The firm targets companies operating across a broad range of sectors and industries. It participates in pre-seed, seed, early, later and growth stage transactions. The firm invests in funds. It also acquires minority interest. | Private Equity Investor | 01/01/2022 |
Education of Peter Davies
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
18
1st degree connections
4
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Bionomics Ltd.
Bionomics Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutics for cancer and diseases of the central nervous system | Health Technology |
The University of Edinburgh
 The University of Edinburgh Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Apeiron Investment Group Ltd.
Apeiron Investment Group Ltd. Investment ManagersFinance Apeiron Investment Group invests in both public and private companies located across the globe primarily in the United States. The firm targets companies operating across a broad range of sectors and industries. It participates in pre-seed, seed, early, later and growth stage transactions. The firm invests in funds. It also acquires minority interest. | Finance |
Leaf4life, Inc.
Leaf4life, Inc. Miscellaneous Commercial ServicesCommercial Services LEAF4Life specializes in developing medicines targeting hypoxia-related disorders. The private company is based in Woburn, MA. The company's lead product, LEAF-4L6715, is a proprietary liposomal formulation of transcrocetin aimed at enhancing oxygen diffusion in patients with conditions such as acute respiratory distress syndrome (ARDS), cancer, and cardiovascular diseases. | Commercial Services |
- Stock Market
- Insiders
- Peter Davies
